Isoray Inc (ISR) 0.71 $ISR
IsoRay Announces Fourth Quarter and Year End Fiscal 2016 Financial Results
PR Newswire - Thu Sep 08, 5:31PM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced its financial results for the fourth quarter and fiscal year ended June 30, 2016.
ISR: 0.71 (unch)
IsoRay, Inc. to Present at Rodman & Renshaw 18th Annual Global Investment Conference
PR Newswire - Tue Aug 16, 8:00AM CDT
IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will present at the Rodman & Renshaw 18th Annual Global Investment Conference taking place on September 11-13, 2016 at the Lotte New York Palace Hotel in New York City.
ISR: 0.71 (unch)
Court Issues Ruling on IsoRay Motion to Dismiss Securities Lawsuit
PR Newswire - Thu Jun 02, 3:20PM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today provides an update on its pending securities lawsuit (In re IsoRay, Inc. Securities Litigation).
ISR: 0.71 (unch)
IsoRay Provides Update on Motion to Dismiss Securities Lawsuit
PR Newswire - Mon May 16, 8:00AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today provides an update on its pending securities lawsuit (In re IsoRay, Inc. Securities Litigation).
ISR: 0.71 (unch)
IsoRay Announces Third Quarter Fiscal 2016 Financial Results and Early Conclusions from Ongoing Strategic Review Process
PR Newswire - Tue May 10, 3:05PM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced its financial results for the third quarter and nine months of fiscal 2016, ended March 31, 2016.
ISR: 0.71 (unch)
IsoRay names Thomas LaVoy as CEO
M2 - Fri Jan 15, 6:26AM CST
Medical technology company IsoRay (NYSE MKT:ISR) revealed on Thursday that it has appointed Thomas LaVoy as its chief executive officer, with effect from 15 February 2016.
ISR: 0.71 (unch)
IsoRay Appoints Thomas LaVoy as CEO to Take Office on February 15
PR Newswire - Thu Jan 14, 7:00AM CST
IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the appointment of Thomas LaVoy as CEO effective February 15. He was previously appointed Chairman of the Board when the former Chairman retired on January 7, 2016.
ISR: 0.71 (unch)
Clinical Study Discusses Cost Effectiveness of Surgical Resection and IsoRay's Cesium-131 Intraoperative Brachytherapy
PR Newswire - Wed Jan 13, 7:00AM CST
IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced a peer-reviewed publication of the results of a retrospective study on the cost effectiveness of Cesuim-131 in combination with surgical resection for metastatic brain tumors. While parts of the manuscript were presented at a meeting of the Society for Neuro-Oncology in 2012 in Washington, DC, the research paper - Wernicke, A. Gabriella, et al., "The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors." DOI 10.1007/s11060-015-2026-4 - was published online on January 2, 2016, in the Journal of Neuro-Oncology.
ISR: 0.71 (unch)
IsoRay Chairman and CEO Dwight Babcock to Retire
PR Newswire - Thu Jan 07, 7:00AM CST
IsoRay Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, announced today that Dwight Babcock has informed the Board that he intends to retire effective today. Mr. Babcock began serving on IsoRay's Board in March 2006 and was appointed as Chairman and interim CEO in 2008, and then CEO in 2009.
ISR: 0.71 (unch)
Weill Cornell Medical Clinical Study Demonstrates Cesium-131 Brachytherapy Seeds on a String Surgical Technique Promotes Dose Homogeneity and Minimizes the Risk of Radiation-Induced Injury
Marketwired - Wed Dec 16, 7:30AM CST
IsoRay Inc. (NYSE: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the publication of the results of an independent peer-reviewed study titled: "Surgical Technique and Clinically Relevant Resection Cavity Dynamics Following Implantation of Cesium-131 Brachytherapy in Patients With Brain Metastases."
ISR: 0.71 (unch)
Weill Cornell Clinical Study Notes Cesium-131 Brachytherapy Can Provide a Viable Alternative to Whole Brain Radiotherapy With Excellent Response Rates and Minimal Toxicity
Marketwired - Mon Dec 14, 7:30AM CST
IsoRay Inc. (NYSE: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the recent publication of the peer-reviewed results of a study entitled: "Neurocognitive function and quality of life in patients with newly diagnosed metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial."
ISR: 0.71 (unch)
IsoRay Reports First Quarter Fiscal 2016 Financial Results
Marketwired - Tue Nov 10, 7:31AM CST
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced its financial results for the first quarter of fiscal 2016, which ended September 30, 2015.
ISR: 0.71 (unch)
IsoRay's Proprietary Cesium-131 Product Line Will Be on Display at the American Society for Radiation Oncology (ASTRO) Convention
Marketwired - Wed Oct 14, 7:15AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth (505) at the 57thAnnual Meeting of the American Society for Radiation Oncology (ASTRO). The annual meeting will take place October 18-21, 2015 in San Antonio, Texas at the Henry B. Gonzalez Convention Center. According to IsoRay CEO Dwight Babcock, "The medical community is becoming increasingly aware of the innovative alternatives that our products offer as an important advance over previous brain, lung, prostate and gynecologic cancer treatments."
ISR: 0.71 (unch)
IsoRay, Inc. Reports 9% Revenue Increase for Fiscal Year 2015
Marketwired - Tue Sep 15, 7:15AM CDT
IsoRay, Inc. (NYSE MKT: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced its financial results for the year and quarter ended June 30, 2015.
ISR: 0.71 (unch)
IsoRay Up 6.9%, Shares Break Through Resistance (ISR)
Comtex SmarTrend(R) - Fri Aug 28, 12:49PM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 6.9% to $1.46 on 1.1x average daily volume. IsoRay has traded 510,000 shares thus far today, vs. average volume of 481,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's -0.7%) and outperformed the S&P 500 (6.9% to the S&P's -0.6%) during today's trading.
ISR: 0.71 (unch)
Hot Stock: IsoRay, Shares Gain 6.6% (ISR)
Comtex SmarTrend(R) - Mon Aug 17, 10:16AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 6.6% to $1.62 on 1.2x average daily volume. Thus far today, IsoRay has traded 582,000 shares, vs. average volume of 486,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.2%) and outperformed the S&P 500 (6.6% to the S&P's 0.2%) during today's trading.
ISR: 0.71 (unch)
Isoray, Inc. Announces Appointment of PCG Advisory Group as Investor, Public and Digital Communications Agency of Record
Marketwired - Mon Aug 10, 7:30AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it has appointed PCG Advisory Group (PCG) as its investor, public and digital communications agency of record.
ISR: 0.71 (unch)
Stock to Watch: IsoRay Up 5.8% (ISR)
Comtex SmarTrend(R) - Wed Aug 05, 11:44AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 5.8% to $1.64 on 3.2x average daily volume. IsoRay has traded 1.4 million shares thus far today, vs. average volume of 439,000 shares per day. The stock has outperformed the Dow (5.8% to the Dow's -0.1%) and outperformed the S&P 500 (5.8% to the S&P's 0.3%) during today's trading.
ISR: 0.71 (unch)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Reminds Investors With Losses in IsoRay, Inc. of July 21, 2015 Deadline
BusinessWire - Fri Jul 17, 8:42PM CDT
Goldberg Law PC (www.Goldberglawpc.com) reminds investors in IsoRay, Inc. ("IsoRay" or the "Company"
(NYSE: ISR), who purchased or otherwise acquired shares between May 20, 2015 and May 21, 2015, inclusive (the "Class Period", of the July 21, 2015 deadline to file a motion to be appointed as lead plaintiff.
ISR: 0.71 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of IsoRay, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of July 21, 2015
BusinessWire - Fri Jul 17, 8:30AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
ISR: 0.71 (unch)
IsoRay Announces Fourth Quarter and Year End Fiscal 2016 Financial Results
PR Newswire - Thu Sep 08, 5:31PM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced its financial results for the fourth quarter and fiscal year ended June 30, 2016.
ISR: 0.71 (unch)
IsoRay, Inc. to Present at Rodman & Renshaw 18th Annual Global Investment Conference
PR Newswire - Tue Aug 16, 8:00AM CDT
IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will present at the Rodman & Renshaw 18th Annual Global Investment Conference taking place on September 11-13, 2016 at the Lotte New York Palace Hotel in New York City.
ISR: 0.71 (unch)
Court Issues Ruling on IsoRay Motion to Dismiss Securities Lawsuit
PR Newswire - Thu Jun 02, 3:20PM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today provides an update on its pending securities lawsuit (In re IsoRay, Inc. Securities Litigation).
ISR: 0.71 (unch)
IsoRay Provides Update on Motion to Dismiss Securities Lawsuit
PR Newswire - Mon May 16, 8:00AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today provides an update on its pending securities lawsuit (In re IsoRay, Inc. Securities Litigation).
ISR: 0.71 (unch)
IsoRay Announces Third Quarter Fiscal 2016 Financial Results and Early Conclusions from Ongoing Strategic Review Process
PR Newswire - Tue May 10, 3:05PM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced its financial results for the third quarter and nine months of fiscal 2016, ended March 31, 2016.
ISR: 0.71 (unch)
IsoRay names Thomas LaVoy as CEO
M2 - Fri Jan 15, 6:26AM CST
Medical technology company IsoRay (NYSE MKT:ISR) revealed on Thursday that it has appointed Thomas LaVoy as its chief executive officer, with effect from 15 February 2016.
ISR: 0.71 (unch)
IsoRay Appoints Thomas LaVoy as CEO to Take Office on February 15
PR Newswire - Thu Jan 14, 7:00AM CST
IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the appointment of Thomas LaVoy as CEO effective February 15. He was previously appointed Chairman of the Board when the former Chairman retired on January 7, 2016.
ISR: 0.71 (unch)
Clinical Study Discusses Cost Effectiveness of Surgical Resection and IsoRay's Cesium-131 Intraoperative Brachytherapy
PR Newswire - Wed Jan 13, 7:00AM CST
IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced a peer-reviewed publication of the results of a retrospective study on the cost effectiveness of Cesuim-131 in combination with surgical resection for metastatic brain tumors. While parts of the manuscript were presented at a meeting of the Society for Neuro-Oncology in 2012 in Washington, DC, the research paper - Wernicke, A. Gabriella, et al., "The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors." DOI 10.1007/s11060-015-2026-4 - was published online on January 2, 2016, in the Journal of Neuro-Oncology.
ISR: 0.71 (unch)
IsoRay Chairman and CEO Dwight Babcock to Retire
PR Newswire - Thu Jan 07, 7:00AM CST
IsoRay Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, announced today that Dwight Babcock has informed the Board that he intends to retire effective today. Mr. Babcock began serving on IsoRay's Board in March 2006 and was appointed as Chairman and interim CEO in 2008, and then CEO in 2009.
ISR: 0.71 (unch)
Weill Cornell Medical Clinical Study Demonstrates Cesium-131 Brachytherapy Seeds on a String Surgical Technique Promotes Dose Homogeneity and Minimizes the Risk of Radiation-Induced Injury
Marketwired - Wed Dec 16, 7:30AM CST
IsoRay Inc. (NYSE: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the publication of the results of an independent peer-reviewed study titled: "Surgical Technique and Clinically Relevant Resection Cavity Dynamics Following Implantation of Cesium-131 Brachytherapy in Patients With Brain Metastases."
ISR: 0.71 (unch)
Weill Cornell Clinical Study Notes Cesium-131 Brachytherapy Can Provide a Viable Alternative to Whole Brain Radiotherapy With Excellent Response Rates and Minimal Toxicity
Marketwired - Mon Dec 14, 7:30AM CST
IsoRay Inc. (NYSE: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the recent publication of the peer-reviewed results of a study entitled: "Neurocognitive function and quality of life in patients with newly diagnosed metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial."
ISR: 0.71 (unch)
IsoRay Reports First Quarter Fiscal 2016 Financial Results
Marketwired - Tue Nov 10, 7:31AM CST
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced its financial results for the first quarter of fiscal 2016, which ended September 30, 2015.
ISR: 0.71 (unch)
IsoRay's Proprietary Cesium-131 Product Line Will Be on Display at the American Society for Radiation Oncology (ASTRO) Convention
Marketwired - Wed Oct 14, 7:15AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth (505) at the 57thAnnual Meeting of the American Society for Radiation Oncology (ASTRO). The annual meeting will take place October 18-21, 2015 in San Antonio, Texas at the Henry B. Gonzalez Convention Center. According to IsoRay CEO Dwight Babcock, "The medical community is becoming increasingly aware of the innovative alternatives that our products offer as an important advance over previous brain, lung, prostate and gynecologic cancer treatments."
ISR: 0.71 (unch)
IsoRay, Inc. Reports 9% Revenue Increase for Fiscal Year 2015
Marketwired - Tue Sep 15, 7:15AM CDT
IsoRay, Inc. (NYSE MKT: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced its financial results for the year and quarter ended June 30, 2015.
ISR: 0.71 (unch)
IsoRay Up 6.9%, Shares Break Through Resistance (ISR)
Comtex SmarTrend(R) - Fri Aug 28, 12:49PM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 6.9% to $1.46 on 1.1x average daily volume. IsoRay has traded 510,000 shares thus far today, vs. average volume of 481,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's -0.7%) and outperformed the S&P 500 (6.9% to the S&P's -0.6%) during today's trading.
ISR: 0.71 (unch)
Hot Stock: IsoRay, Shares Gain 6.6% (ISR)
Comtex SmarTrend(R) - Mon Aug 17, 10:16AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 6.6% to $1.62 on 1.2x average daily volume. Thus far today, IsoRay has traded 582,000 shares, vs. average volume of 486,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.2%) and outperformed the S&P 500 (6.6% to the S&P's 0.2%) during today's trading.
ISR: 0.71 (unch)
Isoray, Inc. Announces Appointment of PCG Advisory Group as Investor, Public and Digital Communications Agency of Record
Marketwired - Mon Aug 10, 7:30AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it has appointed PCG Advisory Group (PCG) as its investor, public and digital communications agency of record.
ISR: 0.71 (unch)
Stock to Watch: IsoRay Up 5.8% (ISR)
Comtex SmarTrend(R) - Wed Aug 05, 11:44AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 5.8% to $1.64 on 3.2x average daily volume. IsoRay has traded 1.4 million shares thus far today, vs. average volume of 439,000 shares per day. The stock has outperformed the Dow (5.8% to the Dow's -0.1%) and outperformed the S&P 500 (5.8% to the S&P's 0.3%) during today's trading.
ISR: 0.71 (unch)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Reminds Investors With Losses in IsoRay, Inc. of July 21, 2015 Deadline
BusinessWire - Fri Jul 17, 8:42PM CDT
Goldberg Law PC (www.Goldberglawpc.com) reminds investors in IsoRay, Inc. ("IsoRay" or the "Company"
(NYSE: ISR), who purchased or otherwise acquired shares between May 20, 2015 and May 21, 2015, inclusive (the "Class Period", of the July 21, 2015 deadline to file a motion to be appointed as lead plaintiff. ISR: 0.71 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of IsoRay, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of July 21, 2015
BusinessWire - Fri Jul 17, 8:30AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
ISR: 0.71 (unch)
